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Abstract. Despite its effectiveness as an antineoplastic drug,
doxorubicin (DOX) is usually associated with cardiotoxicity.
Lovastatin (LOV), a hypolipidemic agent used in the clinic,
has been demonstrated to have antitumoral and antimetastatic
effects in murine models. Since the two agents arrest tumor
cells in different phases of the cell cycle and induce apoptosis,
the goal of this study was to examine the efficacy of a
combination therapy with LOV and low doses of DOX, in an
attempt to obtain an improved antitumoral effect devoid of
toxicity, by using a rat B-cell lymphoma and a mouse
mammary tumor. In the two models, the combined treatment
showed a synergistic antitumoral effect, which is mainly
ascribed to an increased apoptotic response elicited by a
LOV/DOX combination than either agent alone. The
therapeutic benefit demonstrated by the combination treatment
is further emphasized by the lack of toxicity.
Introduction
The loss of the feedback inhibition mechanism that regulates
cholesterol biosynthesis is an important feature of malignant
transformation. It has been reported that cancer cells require
higher amounts of cholesterol and cholesterol precursors than
normal cells (1). Mevalonate, one such precursor, is a critical
component of a complex biochemical pathway whose products,
geranylgeranyl and farnesyl pyrophosphate, are needed for
post-translational modification by the isoprenylation of
proteins like Ras, Rho, Rac and lamin A and B (2).
Isoprenylated Ras proteins associate with the cell membrane
thus becoming capable of regulating the signal transduction
pathways involved in the control of cell growth, differentiation
and survival (3).
The regulation of the mevalonate synthesis is complex,
involving multiple feedback mechanisms in which the end
products of the pathway can regulate the activity of 3-hydroxyl-
3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-
limiting enzyme of this metabolic pathway (4). Lovastatin
(LOV) is a specific competitive inhibitor of HMG-CoA
reductase (5), extensively used in medical practice to treat
hypercholesterolemia (6). LOV has also been shown to arrest
tumor and normal cells in the G1 phase of the cell cycle,
inducing a potent apoptotic response. Its antitumoral and
antimetastatic effects have been demonstrated in experimental
murine models (7-9).
Doxorubicin (DOX) is an anthracycline antibiotic isolated
from the fungus Streptomyces peucetius (10). It induces the
formation of covalent topoisomerase-DNA complexes (11),
cell cycle arrest in the G2 phase and apoptosis (12). DOX has
been in clinical practice since the 1960s, and is considered one
of the most effective drugs in the treatment of lymphomas,
breast adenocarcinomas and other malignant tumors (13).
However, it has been associated with the development of
acute and chronic cardiac toxicity (14).
The aforementioned information, as well as the knowledge
that LOV and DOX are able to stop the cell cycle in the
different phases (G1 and G2, respectively) (12,15), prompted
us to study the feasibility of a combined therapeutic
intervention in which lower doses of DOX could be used.
This therapeutic scheme would likely decrease the toxic
effects of DOX, while improving the effectiveness of the
therapeutic response. Herein, we examined the antitumoral
effect of LOV and the non-toxic doses of DOX in the two
animal tumor models of the rat lymphoma L-TACB and the
mouse mammary adenocarcinoma M-406. We investigated
the effect of the combined treatment by analyzing cell
viability in vitro, studying tumor growth and apoptosis in vivo,
and evaluating the variations of body weight as a general
indicator of animal health status.
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Materials and methods
Animals. Ten to 12-week-old female inbred IIM e/Fm (from
here on e) rats (16) and 6- to 8-week-old inbred CBi female
mice (17) were used throughout and obtained from the
Facultad de Ciencias Médicas, Universidad Nacional de
Rosario, breeding facilities. Animals were fed a commercial
chow and water ad libitum and were maintained in a 12 h
light/dark cycle. All the experiments were done during the
first half of the light cycle and according to animal care
standards of the institution, which complies with the guidelines
issued by the Canadian Council on Animal Care (Ontario,
Canada, 1993).
Drugs. The inactive lactone form of LOV (GADOR,
Argentina) was converted to its active form by dissolving
480 mg in 12.5 ml of 96% ethanol and 18 ml of 0.1 M NaOH at
50˚C for 2 h. The solution was neutralized with 0.1 M HCl to
pH 7.0 and brought to a final volume of 60 ml with distilled
water. Aliquots of this stock solution (20 mM) were stored
frozen at -20˚C until used. DOX (Filaxis S.A., Argentina)
was diluted to 1 mg/ml in saline solution before injection.
Tumors. L-TACB is a poorly-differentiated B-cell lymphoma
that arose spontaneously in an inbred e rat (18). It is maintained
by serial subcutaneous trocar implantation of 1 mm3 tumor
fragments (~106 cells) in syngeneic rats. M-406 is a type B
semi-differentiated mammary adenocarcinoma according to
Squartini's classification (19) which occurred spontaneously in
an inbred CBi female mouse (20). It is maintained in vivo in
syngeneic mice.
Chemosensitivity assay. L-TACB and M-406 cells obtained
by mechanical disruption of subcutaneous primary tumors
excised 14 days after challenge, were suspended in RPMI-
1640 culture medium (Sigma Chemical Co., St. Louis, MO)
and supplemented with 10% fetal bovine serum (FBS, Natocor,
Córdoba, Argentina). Cell suspensions with >95% viability
were seeded in 96-well flat-bottomed microplates (Corning
Costar) at 1x105 cells per well in a 200 μl complete culture
medium. Four groups were established to test the effect of
the different treatments on cell viability: 1) control, without
treatment; 2) LOV, treated with 20 mM LOV; 3) DOX, treated
with 1 mg/ml (L-TACB) or with 8 mg/ml (M-406) and 4)
LOV + DOX, treated with 20 mM LOV plus 1 or 8 mg/ml
DOX (L-TACB and M-406 cells, respectively). After 24 h
incubation at 37˚C in a 5% CO2 humidified atmosphere, a
trypan blue dye exclusion test was performed and cell viability
was determined. The determinations were done in quadrup-
licate.
In vivo experimental models. Rats and mice were injected
subcutaneously in the right flank with L-TACB and M-406
fragments (~106 cells), respectively, on day 0. The animals
were distributed in four groups and injected by i.p. route. For
M-406: 1) saline (control group); 2) LOV (25 mg/kg of body
weight) three times a week from day 5 to 21; 3) DOX (1 mg/kg
of body weight), twice a week from day 5-21; 4) LOV + DOX
as in groups 2 and 3. For L-TACB: 1) saline (control group);
2) LOV (25 mg/kg of body weight) daily from day 0 to 4; 3)
DOX (0.5 mg/kg) on day 10 and 4) LOV + DOX as in groups
2 and 3. The treatment schedule for each tumor model was
chosen based on several regimens tested before with different
DOX and LOV doses or different times for initiation of the
therapy to achieve a better antitumoral effect with a lesser
toxicity (data not shown). Tumor diameters were measured
twice a week with a caliper to calculate tumor volume using
the formula v = 0.4 (ab2), where v is the volume (cm3); a,
largest diameter (cm) and b, smallest diameter (cm). Body
weights were recorded twice a week throughout the
experiments in addition to monitoring the general health
status for signs and symptoms of toxicity. The animals were
sacrificed on days 21 (L-TACB) or 26 (M-406), and their
tumors resected and processed for histological examination.
The end point of each experiment was set to the day in which
the tumors of the control animals reached the maximum
permitted volume.
Immunohistochemistry. Excised tumors were fixed in 10%
buffered formalin and embedded in paraffin. After the
deparaffinization and re-hydration of the sections, endogenous
peroxidase was quenched using 3% hydrogen peroxide for
5 min. Non-specific binding was blocked with normal goat
serum. Slides were washed for 5 min with tris-buffered saline
solution containing Tween-20 at pH 7.6 and incubated with:
a) rabbit anti-Bcl-2 antibody (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) (1:50) followed by incubation with horse-
radish peroxidase-conjugated goat anti-rabbit IgG antibody
(Dako) (1:150) or, b) mouse anti-Bax antibody (Santa Cruz
Biotechnology) (1:50) followed by incubation with Vectastain®
Elite ABC (Mouse IgG, Vector Laboratories, Burlingame,
CA). Immunostainings were developed with 3,3'-diamino-
benzidine (Sigma) and the sections were lightly counterstained
with methyl green. Negative controls were carried out by
omitting the primary antibody. Slides were washed in tap water,
dehydrated and mounted with glass coverslips. The intensity
of Bcl-2 and Bax staining in tumor lesions was assessed at
high power (x400) and graded on a scale of 0 to +4 by two
independent investigators blinded to sample identity, with 0
indicating undetectable staining and +4 the strongest staining.
TUNEL assay. The level of intratumoral apoptosis was
determined by the terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate-peroxidase nick end
labeling (TUNEL) technique. Briefly, apoptotic cells were
identified in the sections using the TUNEL method (ApopTag®
Peroxidase in situ apoptosis detection kit for immunoperoxi-
dase staining, Intergen Company, Purchase, NY) following the
manufacturer's instructions. Apoptotic cells were counted in
10 microscopic fields, chosen at random, at a magnification of
x100.
Statistical analysis. Data were statistically analyzed using
Student's t-test. Values of P<0.05 were considered statistically
significant.
Results
The effect of LOV and DOX on tumor cell viability. The in vitro
cytotoxic effect of treatments with LOV, DOX or the combin-
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ation of the two drugs was studied on M-406 and L-TACB
cells by measuring cell viability. Fig. 1 shows the effect of
the different treatments on tumor cell viability after 24 h
culture. Treatment with LOV or DOX alone induced a
significant decrease in cell viability as compared to the
control. Notably, the combined treatment (LOV + DOX)
produced a synergistic effect on tumor cell viability, which was
statistically lower than that obtained with each single drug in
the two tumor models.
The effect of LOV and DOX treatment on in vivo tumor growth.
In vivo studies were performed to examine whether our in vitro
findings had potential therapeutic significance. The doses of
LOV and DOX used in combination, were chosen among
several tested (results not shown), and were those that resulted
in a significant therapeutic response with negligible toxic
effects. The schedules finally chosen were LOV (25 mg/kg)
three times a week from day 5 to 21 plus DOX (1 mg/kg), twice
a week from day 5 to 21 for the M-406 tumor model and LOV
(25 mg/kg) daily from day 0 to 4, plus DOX (0.5 mg/kg) on
day 10 for the L-TACB tumor model. At the doses used,
neither LOV nor DOX exerted a significant antitumoral effect
on either of the tumor models as single drugs, as compared to
the control groups. Conversely, the combined treatment with
LOV and DOX delayed the tumor growth in the two tumor
systems significantly. At the end of the experiment, the
combined treatment induced a reduction in tumor size of 42 and
35% for M-406 and L-TACB, respectively, when compared to
the controls (p<0.05) (Fig. 2).
In order to assess the toxicity of the different treatments,
we recorded body weight throughout the experiment, since
its variation is a good indicator of general health status. At the
end of the experiment, the mean increase in body weight of
the animals in the control groups (11.7 and 11.3% for M-406
and L-TACB, respectively) was higher than those in the
treated groups (range of increase: 3.9-8.6%, respectively).
This difference in weight gain may be ascribed in part to
significantly larger tumor masses in the control groups.
Nevertheless, it should be pointed out that the aim of this
analysis was not to compare differences in body weights
among the different treatment groups, but to evaluate whether
a reduction in body weight that happened within each group
could be used as an indicator of toxicity. In this respect, it is
important to point out that none of the treated animals exhibited
weight loss during the experiment. The evolution of the weight
gain during the period studied is plotted in Fig. 3 as the
percentage of its value at the beginning of the experiment for
each treatment group. Moreover, no alterations in motor
activity, fur quality, food intake, reflexes and breathing were
observed, this being indicative of a treatment with low or no
toxicity. Also, no drug-related deaths were observed.
The effect of LOV and DOX on in vivo tumor apoptosis. The
induction of apoptosis by DOX and LOV, either alone or in
combination, was assessed by estimating the number of
TUNEL-positive cells in the two tumor models at the end of
the experiment (Fig. 4). Only M-406 and L-TACB tumors
harvested from animals treated with LOV + DOX showed a
significant increase in the number of apoptotic cells when
compared to tumors in the control groups (p<0.05). The
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Figure 1. The in vitro effect of LOV, DOX and their combination on tumor
cell viability. The data are mean ± SEM of viable cells as determined by
the trypan blue exclusion test. M-406: control vs. LOV + DOX, LOV vs.
LOV + DOX, DOX vs. LOV + DOX, P<0.001, control vs. DOX P<0.01.
L-TACB: control vs. LOV, control vs. DOX, control vs. LOV + DOX, LOV
vs. LOV + DOX, P<0.001, DOX vs. LOV + DOX, P<0.01. The statistical
significance of the differences between the groups was assessed by Student's
t-test. Each experiment was performed in quadruplicate.
Figure 2. The effect of the treatment with LOV, DOX or LOV + DOX on
the tumor growth. The data for each time-point are mean ± SEM (M-406,
n=12 and L-TACB, n=9 per treatment group). The arrowheads indicate
specific times at which LOV or DOX were administered. M-406 (day 21) and
L-TACB (day 20): control vs. LOV + DOX, P<0.05 (Student's t-test).
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expression of the anti- and pro-apoptotic molecules Bcl-2 and
Bax, respectively, was also assessed immunohistochemically
in the two tumors under the different treatments. No significant
modification in the expression of Bcl-2 was evident in the
tumors from the combined treatment as well as the single
treatment groups with respect to the control tumors (data not
shown). On the contrary, the expression of Bax was higher in
the LOV + DOX treated tumors than in the control tumors
(Fig. 5). Bax expression in tumors treated either with LOV or
DOX, as single drugs, was similar to that observed in the
controls or showed intermediate levels of expression. The
intensity of Bax expression in M-406 was 0 (undetectable) in
tumors from the control and DOX single treatment groups,
+2 in LOV-treated tumors and +3 in the combined treatment
group LOV + DOX. In L-TACB tumors, Bax expression was
+2 in control samples, +3 in the samples from the two single
treatments (LOV or DOX) and +4 in the LOV + DOX
combined treatment samples.
Discussion
One of the current goals in cancer therapy is to reduce the
development of side effects of chemotherapy and radiotherapy
while retaining their antitumoral capacity. As we have already
demonstrated in the sarcoma and lymphoma rat tumor models
(8,9), LOV has antitumoral and/or antimetastatic activity, with
no observable toxicity at the dose and schedule used. Other
authors have also shown the antitumoral effect of LOV either
alone (7,21) or in combination with different drugs (22-24).
Based on the above-mentioned results, and taking into
account the known ability of LOV and DOX to stop the cell
cycle in different phases (12,15), we investigated whether the
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Figure 3. Evolution of body weight. The data are plotted as a percentage of
body weight at the beginning of the experiment; each time-point is mean ±
SEM (M-406, n=12 and L-TACB, n=9 per treatment group), Student's t-test.
Figure 4. Apoptosis of M-406 and L-TACB cells treated with LOV, DOX or
LOV + DOX, as determined by TUNEL staining. The data are mean ± SEM
of TUNEL-positive cells per microscopic field (magnification, x100). M-406:
control vs. LOV + DOX, LOV vs. LOV + DOX, DOX vs. LOV + DOX,
P<0.05. L-TACB: control vs. LOV + DOX, DOX vs. LOV + DOX, P<0.05,
LOV vs. LOV + DOX, P<0.01 (Student's t-test).
Figure 5. The immunohistochemical analysis of Bax expression in sections
of M-406 and L-TACB tumors. M-406: (A) control, (B) LOV + DOX and
L-TACB: (C) control, (D) LOV + DOX (magnification, x400). Tissue
samples were obtained after 21 and 20 days of tumor challenge with M-406
or L-TACB, respectively. The intensity of Bax expression was higher in the
tumors of the animals treated with LOV + DOX (B and D) when compared
to tumors of the non-treated animals (A and C), respectively.
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combination of low doses of DOX with LOV would result in
high therapeutic efficacy with low or no toxic side-effects.
Previous results showing that LOV can reduce the cardio-
toxicity produced by DOX (25), as well as those indicating
that the therapeutic efficacy of DOX and its derivatives is
improved when combined with other drugs (26), also supported
our selection of DOX for the combined treatments in the
mammary adenocarcinoma and lymphoma tumor models
used herein.
We found that low doses of LOV or DOX, when used as
single agents, decrease tumor cell viability in the in vitro
assays. Notably, the use of the two drugs in combination
induced a significant increase in cytotoxicity with respect to
each single treatment. These results are in agreement with
those obtained by Feleszko et al (27) in sarcoma, colon and
lung carcinoma tumor-models. The combination of LOV with
cisplatin (23), sulindac (28) or paclitaxel (29) also yielded
similar results. Riganti et al recently demonstrated that statins
revert the resistance of a human malignant mesothelioma cell
line to DOX (30). Contrasting with the results mentioned
above, Bardeleben et al (31) working with CHO-K1, HepG2
and Jurkat cells, found that pretreatment with LOV rendered
them resistant to DOX. Such a disparity between the results
from several laboratories, including our own, is the conse-
quence of differences in the experimental conditions used, the
cell type assayed and/or the presence or not of a mutated ras
gene. Certainly, contradictory results such as those described
deserve further studies, in vitro and in vivo.
The enhanced cytotoxic effect of the combined treatment
observed in the in vitro experiments for the two tumors led us
to study this drug combination in an in vivo setting. The
simultaneous administration of LOV and DOX to M-406-
bearing mice resulted in antitumoral activity not achieved by
DOX when given alone. While the rate of tumor growth in
animals treated with either agent did not differ from the
controls in the period studied, a significant decrease in tumor
volume was demonstrated in the mice receiving the combined
treatment. The outcome in the lymphoma L-TACB model
was similar to that observed in the mammary adenocarcinoma
M-406. Tumor volumes on days 20 (L-TACB) or 21 (M-406)
were smaller in LOV + DOX treated animals when compared
to each control group, indicating a delay in tumor growth.
These in vivo results are in agreement with those obtained by
Feleszko et al with melanoma cell lines (32). The treatment
schedules employed [administration of LOV and DOX in a
sequential (M-406) or simultaneous (L-TACB) manner] were
the best of several tested, resulting in a significantly diminished
growth rate when compared to the controls. It cannot be
concluded from our experiments whether LOV or DOX
modified the pharmacokinetic properties of each other.
However, at least for the L-TACB tumor model, we can
assume that such an alteration did not occur, because the last
injection of LOV, a drug with a short half life, was given 6
days before beginning the administration of DOX.
Body weight, a variable currently used as an indicator of
health status, did not decrease in any of the groups during the
period studied, for either of the tumors used. On the contrary,
a steady increase of body weight was observed throughout
the experiments. This result, together with the lack of clinical
signs of drug toxicity such as anorexia, cachexia, raffled fur
or skin tenting, supports our hypothesis that the combined
treatment is able to preserve the antitumoral efficacy of
higher drug doses while decreasing its toxicity.
It has been demonstrated that statins, alone or in
combination with other drugs, are able to induce apoptosis in
different tumor cells (33,34). Since the enhancement of
apoptosis may be a mechanism implicated in the in vivo
antitumoral effect, the presence of apoptotic cells in tumor
tissue was evaluated by the TUNEL assay. The results
obtained are in agreement with those derived from the in vitro
and in vivo experiments. The combined treatments in M-406
and L-TACB resulted in tumors with a higher number of
apoptotic cells than in all the other experimental groups. In
the two tumor models, the level of apoptosis determined in
the tumors obtained from animals treated with a single drug
did not differ from that of the controls. The amount of
apoptosis induced by LOV or DOX alone was not enough to
reach the threshold needed to evince an effect on tumor
development. On the contrary, the combined treatment affected
tumor growth, suggesting that LOV was able to increase the
levels of apoptosis induced by a low dose of DOX.
There are several molecules involved in the activation and
inhibition of apoptosis, Bax and Bcl-2 being two of the most
conspicuous. The immunohistochemical study of these
molecules in the tumoral tissue, used to assess their possible
modulation by the combined treatment, showed that Bcl-2
expression was not significantly affected, while the expression
of Bax was evidently up-regulated in the lymphoma and the
adenocarcinoma tumors. Therefore, one of the molecules
involved in enhanced apoptosis as produced by the combined
treatment, would be Bax. However, additional molecules
regulating apoptosis other than Bax should not be excluded
as responsible of the effect due to the combined treatment
and, therefore, this deserves future research.
Other mechanisms may also be responsible for the
increased apoptotic level achieved with the administration of
the combined treatment. Of these, the effect of LOV on the
p21ras protein function is particularly attractive, since the
activated p21ras protein may alter the development of
apoptosis through the PI3K pathway (35). In addition, the
pharmacological action of LOV on cancer cells is observed
even in those cells with non-mutated ras oncogenes (36).
The inhibition of HMG-CoA reductase by LOV implies a
decreased synthesis of isoprenyl groups like farnesyl. Since
farnesylation is necessary to anchor p21ras to the cell
membrane and enable this protein to function as a signal
transducer (3), LOV treatment would result in the impairment
of the p21 function. In agreement with this assumption, we
previously found that treatment of L-TACB-bearing rats with
LOV diminished the levels of p21ras tethered to the membrane
in tumors with respect to non-treated animals significantly
(37). These results suggest that, under our experimental
conditions, LOV inhibits the membrane association of p21ras
in L-TACB cells. Thus, the decrease of in vitro cell viability
and the enhancement of apoptosis in vivo, observed when
LOV was associated with DOX, could be partially explained by
the known involvement of the p21ras protein in proliferation
signaling (38,39), as well as by the inhibition of apoptosis
(40,41), which would add to the known effect of DOX on the
two parameters (12).
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It can be argued that the direct effect of LOV on its
molecular target is reversible after its withdrawal. Nevertheless,
our past and present experimental results show that the
indirect effect(s) of the drug is (are), at least in part, non-
reversible. We previously reported that an identical schedule
of LOV administration as in the present experiments led to the
inhibition of metastasis development in the L-TACB tumor-
model (9). In general, it is accepted that the development of the
invasive and metastatic phenotypes is not an early event in
tumor progression. For this reason, it is reasonable to consider
that the treatment with LOV on days 0 to 4 would affect
events that take place later on. Moreover, the inhibition of the
p21ras membrane anchorage on L-TACB cells determined
four days after LOV withdrawal, showed a decrease of the
p21ras protein in the membrane fraction, indicating that the
indirect effect of LOV was still occurring (37).
In summary, we have demonstrated the feasibility of
treating different tumor types with a combination of low
doses of DOX and LOV and obtaining a delay in tumor growth
without signs of toxic side effects. These results provide
additional information on the role of statins as enhancers of
the cytotoxic effect of chemotherapeutic drugs. Moreover,
the therapeutic use of statins in combination with low-dose
standard chemotherapy could fulfill the ever-present aim of
cancer treatment to achieve an optimal antitumoral effect
with minimal toxicity. Since LOV pharmacodynamics and
pharmacokinetics are well characterized, it is foreseeable that
it could be incorporated in combination with cytotoxic drugs
into phase I clinical trials in the near future.
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